Inozyme Pharma Statistics

Total Valuation

Inozyme Pharma has a market cap or net worth of $329.69 million. The enterprise value is $209.86 million.

Market Cap	329.69M
Enterprise Value	209.86M

Important Dates

The next estimated earnings date is Tuesday, August 6, 2024, before market open.

Earnings Date	Aug 6, 2024
Ex-Dividend Date	n/a

Share Statistics

Inozyme Pharma has 61.86 million shares outstanding. The number of shares has increased by 41.29% in one year.

Shares Outstanding	61.86M
Shares Change (YoY)	+41.29%
Shares Change (QoQ)	-0.16%
Owned by Insiders (%)	0.52%
Owned by Institutions (%)	92.73%
Float	37.91M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	2.77
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 14.05, with a Debt / Equity ratio of 0.39.

Current Ratio	14.05
Quick Ratio	n/a
Debt / Equity	0.39
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-15.55

Financial Efficiency

Return on equity (ROE) is -58.70% and return on invested capital (ROIC) is -49.33%.

Return on Equity (ROE)	-58.70%
Return on Assets (ROA)	-42.00%
Return on Capital (ROIC)	-49.33%
Revenue Per Employee	n/a
Profits Per Employee	-$1.31M
Employee Count	59
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -18.25% in the last 52 weeks. The beta is 1.52, so Inozyme Pharma's price volatility has been higher than the market average.

Beta (5Y)	1.52
52-Week Price Change	-18.25%
50-Day Moving Average	4.72
200-Day Moving Average	4.65
Relative Strength Index (RSI)	61.89
Average Volume (20 Days)	360,966

Short Selling Information

The latest short interest is 4.13 million, so 6.67% of the outstanding shares have been sold short.

Short Interest	4.13M
Short Previous Month	2.73M
Short % of Shares Out	6.67%
Short % of Float	10.88%
Short Ratio (days to cover)	11.73

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-81.62M
Pretax Income	-77.11M
Net Income	-77.11M
EBITDA	-71.14M
EBIT	-72.45M
Earnings Per Share (EPS)	-$1.37

Full Income Statement

Balance Sheet

The company has $166.46 million in cash and $46.64 million in debt, giving a net cash position of $119.83 million or $1.94 per share.

Cash & Cash Equivalents	166.46M
Total Debt	46.64M
Net Cash	119.83M
Net Cash Per Share	$1.94
Equity (Book Value)	118.84M
Book Value Per Share	1.92
Working Capital	161.92M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$77.44 million and capital expenditures -$155,000, giving a free cash flow of -$77.59 million.

Operating Cash Flow	-77.44M
Capital Expenditures	-155,000
Free Cash Flow	-77.59M
FCF Per Share	-$1.26

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Inozyme Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-41.29%
Shareholder Yield	-41.29%
Earnings Yield	-23.39%
FCF Yield	-23.53%

Analyst Forecast

The average price target for Inozyme Pharma is $16.00, which is 200.19% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$16.00
Price Target Difference	200.19%
Analyst Consensus	Strong Buy
Analyst Count	5
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1